Using Signaling Pathways to Overcome Immune Tolerance to Tumors
- 13 July 2004
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science's STKE
- Vol. 2004 (241) , pe28
- https://doi.org/10.1126/stke.2412004pe28
Abstract
The ability of tumors to evade the immune system is thought to result from the inability of T lymphocytes to recognize and respond to tumor antigens. This lack of T cell response may depend on a failure of dendritic cells to present antigen in the proper context so that T cells become tolerant to tumor antigens rather than primed to undergo an immune response. The inability of tumor-associated dendritic cells to effectively present antigen may in turn depend on inhibitory factors in the tumor milieu. Recent experiments suggest that the administration of toll-like receptor ligands stimulate dendritic cell activation and maturation and may thus help overcome T cell tolerance to tumor antigens. Whether or not such an approach is clinically feasible remains to be seen.Keywords
This publication has 20 references indexed in Scilit:
- Role of dendritic cells in the generation of regulatory T cellsSeminars in Immunology, 2004
- Toll-Like Receptor Signaling PathwaysScience, 2003
- Toll Pathway-Dependent Blockade of CD4 + CD25 + T Cell-Mediated Suppression by Dendritic CellsScience, 2003
- Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?Trends in Immunology, 2002
- T cell clonal anergyPublished by Elsevier ,2002
- Tumour escape from immune surveillance through dendritic cell inactivationSeminars in Cancer Biology, 2002
- Dendritic Cells in Cancer ImmunotherapyAnnual Review of Immunology, 2000
- The discovery of immunologic toleranceHuman Immunology, 1997
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996
- Neonatal Tolerance Revisited: Turning on Newborn T Cells with Dendritic CellsScience, 1996